GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$34.00|
|52 Week High||NT$20.10|
|52 Week Low||NT$42.20|
|1 Month Change||2.41%|
|3 Month Change||-0.59%|
|1 Year Change||54.55%|
|3 Year Change||-19.05%|
|5 Year Change||-57.81%|
|Change since IPO||-62.39%|
Recent News & Updates
GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
|1796||TW Personal Products||TW Market|
Return vs Industry: 1796 exceeded the TW Personal Products industry which returned -17% over the past year.
Return vs Market: 1796 exceeded the TW Market which returned 33.6% over the past year.
Stable Share Price: 1796 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 1796's weekly volatility (4%) has been stable over the past year.
About the Company
GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. The company offers a range of raw materials, such as fermented microbial, fungi, and fruits and vegetables products; probiotics; and herbal extracts and animal derived peptides and powders. It also provides ODM, as well as fermentation toll manufacturing services to companies for the development and manufacture of dietary supplements, functional foods, health food products, and various applications.
GeneFerm Biotechnology Fundamentals Summary
|1796 fundamental statistics|
Is 1796 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1796 income statement (TTM)|
|Cost of Revenue||NT$272.04m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.96|
|Net Profit Margin||7.41%|
How did 1796 perform over the long term?See historical performance and comparison
0.2%Current Dividend Yield
Is GeneFerm Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1796 (NT$34) is trading above our estimate of fair value (NT$1.51)
Significantly Below Fair Value: 1796 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1796 is poor value based on its PE Ratio (43.4x) compared to the TW Personal Products industry average (15x).
PE vs Market: 1796 is poor value based on its PE Ratio (43.4x) compared to the TW market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1796's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1796's PB Ratio (1.9x) is in line with the TW Personal Products industry average.
How is GeneFerm Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GeneFerm Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has GeneFerm Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1796 has high quality earnings.
Growing Profit Margin: 1796 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 1796's earnings have declined by 59.6% per year over the past 5 years.
Accelerating Growth: 1796 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 1796 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).
Return on Equity
High ROE: 1796's Return on Equity (4.5%) is considered low.
How is GeneFerm Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 1796's short term assets (NT$803.2M) exceed its short term liabilities (NT$440.9M).
Long Term Liabilities: 1796's short term assets (NT$803.2M) exceed its long term liabilities (NT$157.4M).
Debt to Equity History and Analysis
Debt Level: 1796's debt to equity ratio (54.3%) is considered high.
Reducing Debt: 1796's debt to equity ratio has increased from 26.1% to 54.3% over the past 5 years.
Debt Coverage: 1796's debt is well covered by operating cash flow (20.7%).
Interest Coverage: 1796's interest payments on its debt are well covered by EBIT (6x coverage).
What is GeneFerm Biotechnology current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1796's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).
High Dividend: 1796's dividend (0.24%) is low compared to the top 25% of dividend payers in the TW market (5.25%).
Stability and Growth of Payments
Stable Dividend: 1796 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.
Growing Dividend: 1796 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 1796 is not paying a notable dividend for the TW market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1796's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
GeneFerm Biotechnology has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.2%.
GeneFerm Biotechnology Co., Ltd.'s employee growth, exchange listings and data sources
- Name: GeneFerm Biotechnology Co., Ltd.
- Ticker: 1796
- Exchange: TPEX
- Founded: 1999
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$1.387b
- Shares outstanding: 40.79m
- Website: https://www.geneferm.com
- GeneFerm Biotechnology Co., Ltd.
- Nangang Software Park
- Building F, 4F-3
- Taipei City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 08:32|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.